Mason Marks, JAMA
Interest in researching and commercializing psychedelic medicines is growing. Substances such as psilocybin and 3,4-methylenedioxymethamphetamine show potential for treating conditions including depression and posttraumatic stress disorder. The Food and Drug Administration (FDA) may soon approve psychedelics for these and other indications.